In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biotechnology
Citing a surplus of alternative vaccines for COVID-19, AstraZeneca is moving to withdraw its Vaxzevria jab from sale. 8 May 2024
Biotechnology
India’s Bharat Biotech (BBIL) and Bilthoven Biologicals (BBio), the Dutch subsidiary of the Serum Institute of India, have inked a pact to manufacture oral polio vaccines (OPVs) in India. 8 May 2024
Pharmaceutical
The US drugmaker Baxter (NYSE: BAX), one of the largest suppliers of dialysis solutions, has suspended its commercial activities in Russia. 8 May 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) has announced the appointment of Danielle Meyrick as chief medical officer (CMO). 8 May 2024
Pharmaceutical
Half of pharma execs are bracing for significant revenue impact from Medicare price negotiations this year, compared to just 22% in 2023, according to research from revenue and compliance experts at Model N. 7 May 2024
Biotechnology
Research from industry analyst GlobalData finds that Chinese companies are leading in the development of antibody-drug conjugates (ADC). 7 May 2024
Pharmaceutical
US biopharma Vertex Pharmaceuticals remains an evergreen pick in the stock market, announcing another set of financial results that exceeded expectations. 7 May 2024
Series C
American inflammation and immunology (I&I) specialist Zenas BioPharma today announced the closing of an upsized $200 million Series C preferred stock financing. 7 May 2024
Pharmaceutical
A trial flop for Massachusetts, USA-based EyePoint Pharmaceuticals has triggered a sell-off from investors, with the price of a share dropping by around half. 7 May 2024
Pharmaceutical
Swiss drug developer Atopia Therapeutics has appointed Dr Grégoire Chevalier as chief executive (CEO). 7 May 2024
Biotechnology
The prospect of a subcutaneous version of Bristol Myers Squibb’s immuno-oncology blockbuster Opdivo (nivolumab) has moved closer. 7 May 2024
Biosimilars
Swiss generics and biosimilars drugmaker Sandoz today announced net sales for the first quarter 2024 of $2.5 billion, an increase of 6% in constant currencies compared to the same quarter of the prior year. 7 May 2024
Pharmaceutical
Three of the world’s largest public health organizations are to join forces, backing a new research and development initiative with $300 million in funding. 7 May 2024
Biosimilars
The first drug for the treatment of ankylosing spondylitis has been registered in the Russian Federation, according to the country’s Ministry of Health and local media reports. 7 May 2024
Pharmaceutical
The British and Irish business of California’s Gilead Sciences has appointed Peter Wickersham to the role of VP and general manager for the UK and Ireland. 7 May 2024
Biotechnology
German biotech BioNTech, which shot into the limelight with the development of the most successful COVID-19 vaccine, Comirnaty, has reported financial results for the three months ended March 31, 2024. 7 May 2024
Biotechnology
Privately-held Italian drugmaker Chiesi Farmaceutici announced a deal with USA-based Gossamer Bio for a global collaboration and license agreement to develop and commercialize the latter’s seralutinib. 7 May 2024
Pharmaceutical
Catalent and the Novo Nordisk Foundation (as the ultimate parent entity of Novo Holdings and Novo Nordisk) announced that, on May 2, they each received a request for additional information and documentary materials (the second request) from the US Federal Trade Commission (FTC) in connection with the proposed merger. 7 May 2024
Pharmaceutical
Maryland, USA–based glycobiology specialist GlycoMimetics has seen its share price fall around 80% after the failure of a Phase III trial. 7 May 2024
Pharmaceutical
US pharma giant Pfizer on Monday revealed that Dr Andrew Baum will join the company as chief strategy and innovation officer, executive vice president. 7 May 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze